



Resource impact statement

Resource impact

Published: 12 January 2022

www.nice.org.uk

Cancer Drugs Fund technology

NICE has recommended selpercatinib for use within the Cancer Drugs Fund for treating RET fusion-positive advanced non-small-cell lung cancer in adults who need systemic therapy after immunotherapy, platinum-based chemotherapy or both. It is recommended only if the conditions in the [managed access agreement](#) are followed.

This recommendation is not intended to affect treatment with selpercatinib that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.

Selpercatinib will be available to the NHS in line with the managed access agreement with NHS England. As part of this, NHS England and Eli Lilly have a commercial access agreement that makes selpercatinib available to the NHS at a reduced cost. The financial terms of the agreement are commercial in confidence.

The resource impact of selpercatinib will be covered by the Cancer Drugs Fund budget. More evidence on selpercatinib is being collected until sufficient data has been collected to address uncertainties. After this, NICE will decide whether or not to recommend it for use on the NHS and update the guidance. It will be available through the Cancer Drugs Fund until then. Further information can be found in [NHS England's Appraisal and Funding of Cancer Drugs from July 2016 \(including the new Cancer Drugs Fund\) - A new deal for patients, taxpayers and industry](#).

This technology is commissioned by NHS England. Providers are NHS hospital trusts.